1. Lack of Benefit of Ischemic Postconditioning After Routine Thrombus Aspiration During Reperfusion
- Author
-
Henrique Carvalho, Vasco Dias, Sousa Pereira, Filomena Oliveira, Adelino F. Leite-Moreira, Mário Santos, Rui Magalhães, André Luz, Severo Torres, João Silveira, and Sofia Cabral
- Subjects
Male ,medicine.medical_specialty ,Endpoint Determination ,Myocardial Infarction ,Myocardial Reperfusion ,Ventricular Function, Left ,Troponin T ,Coronary thrombosis ,Interquartile range ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Myocardial infarction ,Thrombus ,Ischemic Postconditioning ,Aged ,Thrombectomy ,Pharmacology ,Ejection fraction ,business.industry ,Coronary Thrombosis ,Area under the curve ,Stroke Volume ,Stroke volume ,Middle Aged ,medicine.disease ,Death, Sudden, Cardiac ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objectives: The underutilization of manual thrombus aspiration (MTA) may have reduced the benefits of ischemic postconditioning (PostCon), as it reduces thrombus embolization. We aimed to assess the benefits of PostCon in patients with ST-segment elevation myocardial infarction (STEMI) after the systematic utilization of MTA. Methods: A total of 87 patients were enrolled in a prospective, randomized trial (43 PostCon and 44 controls). After MTA, PostCon was performed on the treatment group by applying 4 cycles of alternate reperfusion and reocclusion (60 seconds each) using the angioplasty balloon. The primary end point was infarct size assessed by the area under the curve (AUC) of troponin T (TnT) activity. The secondary end points were left ventricle ejection fraction (LVEF) and major cardiac events (new myocardial infarction or cardiac death) both at discharge and at follow-up. Results: The AUC for TnT was no different with respect to study arms (median [interquartile range]): PostCon = 8.9 (10.6) versus control = 8.2 (10.6), P = .68. Left ventricle ejection fraction improved from in-hospital to follow-up (9 ± 3 months) for the entire cohort (46.3% ± 7.3% vs 52.2% ± 10.7%, P < .001), with no differences between PostCon and controls (51.6% ± 9.5% vs 52.7% ± 11.9%, P = .89); major cardiac events at 14 ± 4 months of follow-up were also no different (PostCon = 1.0 (2.3%) vs control = 0, P = .49). Conclusion: In patients with STEMI treated with MTA, PostCon offered no benefits to infarct size, LVEF, or major cardiac events.
- Published
- 2015
- Full Text
- View/download PDF